Medical care costs associated with progression of diabetic nephropathy

Diabetes Care

Volumn 34, Issue 11, 2011, Pages 2374-2378

  Nichols, Gregory A ^a   Vupputuri, Suma ^a   Lau, Helen ^b  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; COST OF ILLNESS; COST UTILITY ANALYSIS; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; HYPERTENSION; KIDNEY FAILURE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PROTEIN URINE LEVEL; RENAL SYSTEM PARAMETERS; RETROSPECTIVE STUDY; URINE ALBUMIN TO CREATININE RATIO; AGED; ALBUMINURIA; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLASSIFICATION; ECONOMICS; FOLLOW UP; HEALTH INSURANCE; HEALTH SURVEY; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY; UNITED STATES;

ADULT; AGED; ALBUMINURIA; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; OREGON; POPULATION SURVEILLANCE; SEVERITY OF ILLNESS INDEX;

EID: 84857078072     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0475     Document Type: Article

References (19)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
2. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999;159:1873-1880 (Pubitemid 29424707)
3. Pelletier EM, Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall ME. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy 2008;6:103-112
4. Trivedi HS, Pang MM, Campbell A, Saab P. Slowing the progression of chronic renal failure: economic benefits and patients'perspectives. Am J Kidney Dis 2002;39:721-729 (Pubitemid 34263345)
5. Herman WH, Shahinfar S, Carides GW, et al. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care 2003;26:683-687 (Pubitemid 36929328)
6. Alexander CM, Lyle PA, Keane WF, Carides GW, Zhang Z, Shahinfar S. Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. Kidney Int Suppl 2004;66:S115-S117 (Pubitemid 43361446)
7. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 2011;34(Suppl. 1):S11-S61
8. Hornbrook MC, Goodman MJ, Fishman PA, Meenan RT, O'Keeffe-Rosetti M, Bachman DJ. Building health plan databases to risk adjust outcomes and payments. Int J Qual Health Care 1998;10:531-538 (Pubitemid 29037246)
9. Briggs A, Nixon R, Dixon S, Thompson S. Parametric modelling of cost data: some simulation evidence. Health Econ 2005;14:421-428 (Pubitemid 40514754)
10. Dall TM, Zhang YJ, Chen YJ, Quick WW, Yang WG, Fogli J. The economic burden of diabetes. Health Aff (Millwood) 2010;29:297-303
11. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004;110:32-35 (Pubitemid 38880131)
12. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004;27:1879-1884 (Pubitemid 38989226)
13. Estacio RO, McFarling E, Biggerstaff S, Jeffers BW, Johnson D, Schrier RW. Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM. Am J Kidney Dis 1998;31:947-953 (Pubitemid 28265190)
14. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol 2006;17(Suppl. 2):S90-S97
15. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878
16. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000;355:253-259
17. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-2446 (Pubitemid 351793017)
18. Zoungas S, de Galan BE, Ninomiya T, et al.; ADVANCE Collaborative Group. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 2009;32:2068-2074
19. Ismail-Beigi F, Craven T, Banerji MA, et al.; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-430